These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 35305726)

  • 1. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
    Obajdin J; Davies DM; Maher J
    Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
    Zhang J; Zheng H; Diao Y
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.
    Moscarelli J; Zahavi D; Maynard R; Weiner LM
    Transplant Cell Ther; 2022 Oct; 28(10):650-656. PubMed ID: 35788086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
    Zhuang X; Long EO
    Front Immunol; 2022; 13():840844. PubMed ID: 35585985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-NK cells for cancer immunotherapy: recent advances and future directions.
    Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
    Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
    Jiang D; Zhang J; Mao Z; Shi J; Ma P
    Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cell based immunotherapy against oral squamous cell carcinoma.
    Zhang Y; Xie J; Wu H; Huang J; Zheng D; Wang S; Jia X; He Z; Gong Y; Ju L; Sun Q
    Front Immunol; 2024; 15():1440764. PubMed ID: 39192980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
    Peng XR; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of NK cell-based cancer immunotherapies through receptor engineering.
    Page A; Chuvin N; Valladeau-Guilemond J; Depil S
    Cell Mol Immunol; 2024 Apr; 21(4):315-331. PubMed ID: 38443448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
    Fantini M; Arlen PM; Tsang KY
    Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.